Year 2022 / Volume 114 / Number 6
Letter
Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration

358

DOI: 10.17235/reed.2022.8621/2022

Lucía Madero Velázquez, Roser Muñoz Pérez, Andrés Rodríguez, Lorena Bernal, Beatriz Orts, Laura Sempere, Ana Gutiérrez Casbas,

Abstract
Carboxymaltose iron (Ferinject®) is a formulation for intravenous (iv) administration, used for the treatment of iron deficiency anemia and/or iron deficiency when oral administration of iron is not effective or due to intolerance. Its safety profile is excellent with few, but not nonexistent, side effects. Hypophosphatemia has been described as one of them. It is usually mild, transient and asymptomatic. However, in some cases it may be accompanied by nausea, asthenia, in addition to muscular and neurological symptoms and hematological alterations. It is, therefore, a potentially serious adverse effect whose prevalence is unknown and which requires high clinical suspicion to be detected.
Share Button
New comment
Comments

21/06/2022 0:57:21
Am here to appreciate Dr.Timothy for using his herbal medicine to cure my Herpes virus. since 2016 i have been living with this virus and it has been giving me challenges, I was so perplexed cause i have been taking several drugs to be cured but all of my effort was in vain,one evening i was browsing through the internet then i saw several testimonies about Dr.Timothy curing people from Herpes virus and immediately i contacted his email address i told him about my sickness and he told me that i will be cured within 21 days he gave me some instructions and which i rightly followed. so he prepared a herbal medicine for me and sent it to me which i used for 21 days and everything was like a dream to me and my Herpes virus was totally gone why don't you contact Dr.Timothy he is very good and honest. contact him via email address; goodhealthherbalfoundation@yahoo.com OR website https://5dc41d5b6d60d.site123.me


13/06/2022 11:21:33
Buena información , le tendremos presente


References
1.Musgrove J, Wolf M. Editorial: awareness and prevention of intravenous iron-induced hypophosphatemia. Aliment Pharmacol Ther. 2019;50:611-612.
2.Detlie TE, Lindstrøm JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50:397-406.
3.Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized controlled trials. Anemia. 2012;2012:172104.
4.Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep. 2017;2017:bcr2016219160.
Related articles
Citation tools
Madero Velázquez L, Muñoz Pérez R, Rodríguez A, Bernal L, Orts B, Sempere L, et all. Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration. 8621/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 911 visits.
This article has been downloaded 161 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 19/01/2022

Accepted: 25/01/2022

Online First: 02/02/2022

Published: 07/06/2022

Article Online First time: 14 days

Article editing time: 139 days


Share
This article has been rated by 4 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology